Targeted Oncology Staff

During a Case Based Peer Perspectives event Brian T. Hill, MD, PhD, discussed the case of a 53-year-old patients with chronic lymphocytic leukemia.

Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

Leslie M. Randall, MD, discussed the case of a 49-year-old African American patients with BRCA-mutated ovarian cancer.

Edward Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute in Charlotte, NC, discussed the use of atezolizumab and durvalumab as treatment of a 73-year-old female patient with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

Alex Spira, MD, PhD, director, Virginia Cancer Specialists, Phase I Trial Program, Fairfax, VA, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.

Ronald D. Alvarez, MD, MBA, weighs the pros and cons of adding bevacizumab to olaparib as treatment of a 69-year-old male patients with BRCA-mutant ovarian cancer.

Treatment options for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was discussed by Meredith McKean, MD, MPH and a group of physicians.

During a virtual Case Based Peer Perspective series, Zofia Piotrowska, MD, discussed the case of a 66-year-old man with non–small cell lung cancer and a genetic mutation.

The case of a 49-year-old African American woman with ovarian cancer was discussed during a virtual Case Based Peer Perspective event led by Matthew L. Anderson, MD, PhD.

The case of a 73-year-old Asian patient diagnosed with non–small cell lung cancer and an EGFR exon 19 deletion was discussed during a virtual Case Based Peer Perspectives event, led by Melissa L. Johnson, MD.

During a virtual Case Based Peer Perspectives event, Mark G. Kris, MD, attending physician, Thoracic Oncology Service, William and Joy Ruane chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discussed molecular testing for a 59-year-old patient with poorly differentiated adenocarcinoma of the lung, as wells as the treatment options for the patient.

Mark Agulnik, MD, discussed the guidelines and data supporting possible treatment decisions for an 88-year-old male patients with basal cell carcinoma, during a virtual Case Based Peer Perspectives event.

John V. Heymach, MD, PhD, reviewed the case of a 73-year-old women with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, a discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, David I. Quinn, MD, MBBS, PhD, reviewed the case of a 60-year old male patient with metastatic castration-resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, Nicholas J. Vogelzang, MD, reviewed the case of a 75-year-old man diagnosed with metastatic castration-resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, Paul M. Barr, MD, reviewed the case of a 71-year-old woman with newly diagnosed chronic lymphocytic leukemia and the role of BTK inhibitors in the frontline setting.

Siddhartha Ganguly, MD, reviewed the case of a 51-year-old man with standard-risk multiple myeloma.

During a virtual Case Based Peer Perspectives event, Craig A. Portell, MD, discussed how he would go about treating a patient case with chronic lymphocytic leukemia.

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.

The options for targeted therapy and treatment with hypomethylating agents was discussed during a virtual Case Based Peer Perspectives event, which highlighted the case of a 75-year-old male patient with myelodysplastic syndromes. The discussion was led by James K. McCloskey II, MD.

During a virtual Case Based Peer Perspective event, Cristina Gasparetto, MD, discussed the case of a geriatric male diagnosed with stage II multiple myeloma.

In an interview with Targeted Therapies in Oncology, C. Ola Landgren, MD, PhD, discussed how the availability of daratumumab by subcutaneous administration will affect clinical practice going forward.

Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.

The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.

In a Targeted Oncology case-based peer perspectives live discussion, Charu Aggarwal, MD, MPH, discussed systemic treatment options for stage III non–small cell lung cancer, based on a real case of a 63-year-old male patient.

Based on data from the phase III SOLAR-1 trial, alpelisib (Piqray) has been approved by the FDA for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) has been approved by the FDA for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on findings from the phase III CLL14 trial.